FDA mandates pediatric trials for 200 cancer targets

In a move to spur development of drugs for pediatric populations and require more studies of pediatric cancers, FDA published Tuesday a list of 200 molecular targets for which companies developing directed compounds must conduct pediatric clinical studies. The requirement applies even if the compound has Orphan Drug designation for the pediatric population, or if the adult indication does not occur in children.